Company Product Description Indication Status
Phase I
Antios Therapeutics Inc., of Atlanta ATI-2173 Active site polymerase inhibitor nucleotide Chronic hepatitis B virus infection Completed phase Ib trial; results expected at upcoming medical conference in mid-2021
Exelixis Inc., of Alameda, Calif. XL-102 Oral inhibitor of CDK7 Solid tumors Started study testing safety, tolerability, pharmacokinetics and preliminary antitumor activity of drug alone or in combination with other cancer agents in inoperable locally advanced or metastatic disease
Phase II
Alector Inc., of South San Francisco, and Abbvie Inc., of North Chicago AL-002 Humanized monoclonal antibody targeting TREM2 Early Alzheimer’s disease First participant dosed in Invoke-2 study; primary endpoint is to measure disease progression using Clinical Dementia Rating Sum Boxes
Durect Corp., of Cupertino, Calif. DUR-928 Endogenous sulfated oxysterol and epigenetic regulator Severe alcohol-associated hepatitis Dosed first patient in Ahfirm phase IIb study; primary outcome measure will be 90-day survival rate 
Medigen Vaccine Biologics Corp., of Taipei, Taiwan, and Dynavax Technologies Corp., of Emeryville, Calif. MVC-COV1901 Subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 COVID-19 First participant dosed in trial testing proposed dosing regimen of 2 doses administered intramuscularly 1 month apart
Synairgen plc, of Southampton, U.K. SNG-001 Inhaled interferon beta-1a COVID-19 infection Agent was included in phase II/III Activ-2/A5401 trial sponsored by NIH's NIAID in people with infection but not yet requiring hospitalization; initial evaluation will enroll up to 220 participants, split between study drug and placebo
Zydus Cadila Healthcare Ltd., of Ahmedabad, India Desidustat HIF prolyl hydroxylase-2 inhibitor COVID-19 infection In phase IIb program conducted in Mexico, no participants hospitalized with infection who were in treatment arm required mechanical ventilator vs. 25% of those on standard of care 
Phase III
Astrazeneca plc, of Cambridge, U.K. Calquence (acalabrutinib) BTK inhibitor Chronic lymphocytic leukemia Elevate-RR trial met primary endpoint of noninferior progression-free survival vs. ibrutinib (Imbruvica, Janssen Pharmaceuticals) in adults with previously treated, high-risk disease; trial also met key secondary safety endpoint, showing statistically significantly lower incidence of atrial fibrillation for study drug vs. ibrutinib
Genentech, unit of Roche Holding AG, of Basel, Switzerland Faricimab Bispecific antibody targeting angiopoietin-2 and VEGF-A Wet age-related macular degeneration Identically designed Tenaya and Lucerne studies that collectively enrolled 1,329 participants met primary endpoint, with study drug, dosed at intervals of up to every 16 weeks, producing noninferior BCVA gains vs. aflibercept (Eylea, Regeneron Pharmaceuticals Inc./Bayer AG) dosed every 8 weeks
Macrogenics Inc., of Rockville, Md. Margenza (margetuximab-cmkb) HER2-targeting monoclonal antibody Metastatic breast cancer Pivotal Sophia trial findings in which study drug + chemotherapy showed 24% progression-free survival relative risk reduction vs. trastuzumab + chemotherapy in people with HER2-positive disease (median PFS 5.8 vs. 4.9 months) published in JAMA Oncology 

Notes

For more information about individual companies and/or products, see Cortellis.